A bald man with a mustache wearing a dark suit, light blue shirt, and patterned tie, smiling in front of a plain gray background.

Leslie Citrome, MD, MPH

Adjunct Professor of Psychiatry and Behavioral Sciences, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.

JCP
NNT, NNH, and LHH for Lumateperone
Original Research

March 6, 2023

The benefit-risk assessment of lumateperone was favorable as measured by number-needed-to-treat and number-needed-to-harm analyses.
, , , et al
JCP
Effect of Zuranolone on Anxiety and Insomnia in Postpartum Depression
Original Research

January 30, 2023

Zuranolone was associated with improvements in depressive and anxiety symptoms and was beneficial for insomnia and patient-perceived functional health in patients with PPD.
, , , et al
JCP
Impact-TD Scale: A Clinical Tool to Assess the Impact of Tardive Dyskinesia
Consensus Statement

November 28, 2022

This easy-to-use scale developed by 7 experts measures the impact of TD on patients’ daily functioning.
, , , et al
JCP
Sublingual Dexmedetomidine for Agitation in Schizophrenia
Original Research

October 3, 2022

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or schizoaffective disorder.
, , , et al
JCP
Transdermal HP-3070 for Hostility in Schizophrenia
Original Research

June 6, 2022

Schizophrenia is sometimes accompanied by aggressive, hostile behavior, particularly during the acute phase. This post hoc analysis of a phase 3 study examines the efficacy of transdermal asenapine (HP-3070)...
, , , et al
JCP
Educational Activity

October 12, 2021

Can you recognize risk factors for tardive dyskinesia? Are you familiar with diagnostic criteria? Do you regularly assess patients for the condition? Are you knowledgeable about using new medications...
,
JCP
Academic Highlights

August 31, 2021

Experts offer a review of the fundamentals of diagnosing and treating tardive dyskinesia.
,
JCP
Original Research

June 1, 2021

Many pharmacologic treatment options are available for insomnia. In this study, the clinical utility of the new hypnotic lemborexant is given clinical perspective via the evidence-based medicine tools of...
, , , et al
JCP
Writing, Reviewing, and Publishing Scientific Articles, Part 2: Demystifying the Manuscript Submission Process
Insights

May 24, 2021

Editor of the ASCP Corner shares his thoughts, especially for early career psychiatrists, on writing and submitting your manuscript in such a way as to remove fear from the...
JCP
Original Research

December 15, 2020

Transdermal asenapine administration may address unmet needs in patients with schizophrenia, including improved adherence. This phase 3 study assessed efficacy and safety of HP-3070, an asenapine transdermal system (patch),...
, , , et al
JCP
Consensus Statement

May 19, 2020

The quantification of antipsychotic levels in blood, or therapeutic drug monitoring (TDM), could aid clinicians in numerous challenging scenarios. Learn more about using TDM for dosing decisions in this...
, , , et al
JCP
Original Research

March 10, 2020

Alcohol use disorder is comorbid in 33% of US patients with schizophrenia. Testing the tolerability of olanzapine and samidorphan until the first event of exacerbation of disease symptoms is...
, , , et al

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe